Shuwen Biotech of Hangzhou has launched a proprietary PD-L1 test kit, the first Chinacompany to offer a PD-L1 diagnostic, the company said. The kit is used to determine the expression levels of PD-L1 in tumor tissues. Shuwen said Hengrui Medicine used its kit in clinical trials of its PD-1 drug in patients with esophageal squamous cell carcinoma. The trial showed the PD-1 candidate produced a higher response rate in patients who were positive for PD-L1.
Source: China Biotoday
